Study of the treatment of psoriasis by unani medicine

A Randomized, Open-Label, Active Controlled, Parallel-Group Clinical Study to Compare the Safety and Efficacy of Itrifal Shahtra and Marham Hina with PUVAsol and Petroleum Jelly in the Management of Taqashshur al-Jild (Psoriasis)

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2020/03/023697

Enrollment

Registered

2020-03-02

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L400- Psoriasis vulgaris

Interventions

Intervention1: Group(A) Unani Drugs :Itrifal Shahtra and Marham Hina: Patient will be advised Itrifal Shahtra (semisolid) 6 gm twice daily with Water Orally and Marham Hina(Paste) 5gm will be applied

Eligibility

Inclusion criteria

Inclusion criteria: 1-Patients of any sex in the age group between 18 and 65 years 2-Patients with clinically diagnosed Taqashshur al-Jild (Psoriasis) of plaque-type 3-Psoriasis area severity index (PASI) of >=10%

Exclusion criteria

Exclusion criteria: 1-Patients aged 65 years 2-Pregnant and lactating mothers 3-Significant pulmonary/cardiovascular/hepato-renal dysfunction 4-Known cases of Immunocompromised states (HIV/ AIDS, etc.) 5-Patient not willing to attend treatment schedule regularly

Design outcomes

Primary

Measure	Time frame
The response to treatment will be assessed using the following parameters: 1. Reduction in Psoriasis Area Severity Index (PASI) 2-Improvement in Investigators Global Assessment (IGA) 3-Patientâ??s Global Assessment (PGA) on VAS Timepoint: at base line,4wk,8wk,12wk	—

Secondary

Measure	Time frame
To compare the improvement in quality of life in patients with Psoriasis by PGA ON VAS and IGATimepoint: at base line,4wk,8wk and 12wk	—

Countries

India

Contacts

Public ContactArzeena Jabeen

National Research Institute of Unani Medicine for Skin Disorders

ccrumhqrsnd58@gmail.com8700027178

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026